Send to

Choose Destination
See comment in PubMed Commons below
Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):314-8. doi: 10.1016/j.gcb.2010.01.015. Epub 2010 Mar 5.

Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach.

Author information

  • 1Liver Unit, Hôpital de l'Hôtel-Dieu, 69002 Lyon, France.


Sorafenib has recently been approved as the gold standard therapy for advanced BCLC-C hepatocellular carcinomas. Although significant improvement of survival rates was shown, objective tumor response rates remained low following RECIST criteria in phases 2 and 3 studies. We report the rare case of a patient with a large hepatocellular carcinoma tumor invading suprahepatic veins in which sorafenib led to a very significant regression by about 90% of the tumor bulk, thus allowing at sterilizing the residual tumor tissue by subsequent combination of transarterial intrahepatic chemoembolization and high dose radiotherapy.

Copyright 2010. Published by Elsevier Masson SAS.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Masson (France)
    Loading ...
    Write to the Help Desk